Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CCL5 | P13501 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594985 | 0.84 | PKM (0.39) | RIPK1FFAR1MEN1KMT2ACCL5 | |
| SCHEMBL5435616 | 0.82 | GPR119 (0.53) | MEN1KMT2AKDM4EGPR119MAPT | |
| SCHEMBL3598951 | 0.81 | ALDH1A1 (0.42) | FFAR1KDM4ESLC6A2SLC6A3LMNA | |
| SCHEMBL28754972 | 0.79 | CYP3A4 (0.42) | RIPK1MEN1KMT2AKDM4EGPR119 | |
| SCHEMBL6011500 | 0.74 | CCL5 (0.48) | CCL5CCR5CYP3A4CYP2D6KCNH2 | |
| SCHEMBL3600771 | 0.74 | CCL5 (0.48) | CCL5CCR5CYP3A4CYP2D6KCNH2 | |
| SCHEMBL5439360 | 0.73 | SMN1; SMN2 (0.58) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL27963052 | 0.72 | RPS6KB1 (0.48) | KDM4E | |
| SCHEMBL7497731 | 0.72 | ACHE (0.49) | DRD3 | |
| SCHEMBL5508578 | 0.72 | MEN1 (0.54) | FFAR1MEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-7192973-B2 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5) | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| EP-1742934-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| US-20040267016-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1448548-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042205-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | RIPK1 1199/4885FFAR1 218/4885FKBP1A 2937/4885 |
| US-20040267016-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | CCR5, CCR2, CCR1 | RIPK1 1459/4885FFAR1 193/4885FKBP1A 3592/4885 |
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | CCR5, CCR2, CCL5 | RIPK1 1464/4885FFAR1 209/4885FKBP1A 3775/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | RIPK1 1682/4885FFAR1 355/4885FKBP1A 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.